Primary open-angle glaucoma (POAG) or Ocular hypertension (OH)
Conditions
Interventions
0.003% SNJ-1656 instilled in both eyes, b.i.d. for 4 weeks.
0.01% SNJ-1656 instilled in both eyes, b.i.d. for 4 weeks.
0.03% SNJ-1656 instilled in both eyes, b.i.d. for 4 weeks.
Vehicle instilled in b
Sponsors
Senju Pharmaceutical co.,ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients had POAG or OH 2)IOP (hour 0) POAG:IOP of >=18.0 mmHg and <= 31.0 mmHg OH:IOP of >= 22.0 mmHg and <= 31.0 mmHg 3)Best corrected visual acuity of 0.5 or better 4)Patients who are completed designated washout at confirmation date of IOP 5)Change from baseline IOP (hour 0) at confirmation date of IOP <= 3.0 mmHg
Exclusion criteria
Exclusion criteria: 1)Active retinal disease 2)History of keratorefractive surgery or filtering surgery 3)History of trabeculotomy or laser trabeculoplasty in the study eye 4)Highly visual field loss 5)Corneal abnormalities that would preclude accurate readings with an applanation tonometer 6)Ocular surgery within 90 days 7)Use of contact lenses 8)Any active ocular disease other than glaucoma or OH 9)Uncontrolled systemic disease (eg, hepatic, renal, cardiovascular or endocrine system disease) 10)Women who were pregnant, nursing or who were of childbearing potential, or planning a pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change from baseline intraocular pressure (IOP) at week 4 (Hour 0 and 2) | — |
Countries
Japan
Contacts
Public ContactYoko Minagawa
Senju Pharmaceutical co.,ltd. Clinical Development
Outcome results
None listed